The earnings call reflects a company making significant progress in its clinical programs and preclinical data, with strategic collaborations enhancing market potential. However, financial constraints and the absence of secured partnerships pose challenges. Shareholder concerns regarding the share price remain unaddressed.
Company Guidance
During the Avacta Group plc Interim Results Investor Presentation, several key metrics were discussed regarding the company's clinical programs and financial status. The call highlighted Avacta's progress in its clinical stage programs, notably faridoxorubicin (FAP-Dox or AVA6000) and FAP-exatecan, with the former advancing to Phase Ib and the latter on track for its first patient dosing in Q1 2026. The company presented encouraging preliminary data for faridoxorubicin in salivary gland cancers and outlined plans for further data updates at ESMO 2025. Financially, Avacta reported cash and cash equivalents of GBP 12.65 million as of June 30, 2025, with cash outflows from operations at GBP 12.14 million for the first half of 2025. The management highlighted a renegotiation of the Heights Convertible Bond and a GBP 6.5 million gross fundraising to support quarterly bond payments. Additionally, Avacta anticipates releasing further data on its programs, including a pipeline update leveraging its pre|CISION platform, with an emphasis on strategic partnerships and business development to support its financial strategy and minimize shareholder dilution.
Clinical Program Progress
Avacta's lead program, faridoxorubicin (FAP-Dox or AVA6000), is advancing with promising preliminary data in salivary gland cancers. The company also anticipates dosing the first patient with FAP-exatecan in Q1 2026.
Encouraging Preclinical Data
Updated preclinical data for FAP-exatecan shows durable complete responses in animal models, indicating potential efficacy and durability of the response.
Financial Management
Avacta maintains a cash runway into Q1 2026. Recent financial activities include renegotiation of the Heights Convertible Bond and raising GBP 6.5 million to fund bond payments.
Strategic Collaborations
The Tempus collaboration has confirmed the market opportunity for Avacta's pre|CISION medicines, showing FAP expression in 90% of patients with solid tumors.
Avacta Group plc (GB:AVCT) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:AVCT Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 30, 2025
51.00p
59.50p
+16.67%
Jun 06, 2025
34.25p
32.50p
-5.11%
Sep 30, 2024
51.50p
49.00p
-4.85%
Apr 30, 2024
48.30p
45.75p
-5.28%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avacta Group plc (GB:AVCT) report earnings?
Avacta Group plc (GB:AVCT) is schdueled to report earning on Apr 16, 2026, Before Open (Confirmed).
What is Avacta Group plc (GB:AVCT) earnings time?
Avacta Group plc (GB:AVCT) earnings time is at Apr 16, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.